Prelude Capital Management’s Bicycle Therapeutics BCYC Stock Holding History

Prelude Capital Management’s Portfolio BCYC Stock Details BCYC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-9,061	Closed	-$231K	–	1142
2023 Q2	$231K	Sell	9,061 -3,573	-28%	-$83K	0.02%	783
2023 Q1	$269K	Buy	+12,634	New	+$317K	0.02%	693

Other funds holding BCYC

Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return

Jefferies Financial Group New York $14.6B AUM 40.95% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Point72 Asset Management

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return

Tybourne Capital Management Hong Kong $30.9M AUM 20.1% 1-Year Est. Return

Candriam SCA Strassen, Luxembourg, Luxembourg $19.3B AUM 39.18% 1-Year Est. Return

Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return

Prelude Capital Management's BCYC Position: Q3 2023 in Review

Prelude Capital Management sold out of Bicycle Therapeutics (BCYC) in Q3 2023, closing a stake of 9,061 shares — an estimated $231K sold.

Prelude Capital Management first reported a position in BCYC in Q1 2023 and held it in 2 quarters. The position peaked at $269K in Q1 2023. 101 funds tracked by Wall St. Rank hold BCYC as of Q3 2023.

Prelude Capital Management reported no remaining Bicycle Therapeutics position as of Q3 2023 after selling out during the quarter.
Prelude Capital Management sold 9,061 Bicycle Therapeutics shares in Q3 2023, an estimated $231K.
Prelude Capital Management first reported a position in Bicycle Therapeutics in Q1 2023 and held it in 2 quarters.
Prelude Capital Management's Bicycle Therapeutics position peaked at $269K in Q1 2023.
101 funds tracked by Wall St. Rank held Bicycle Therapeutics as of Q3 2023.

Based on Prelude Capital Management's 13F filing for Q3 2023, filed 14 Nov 2023.